查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1490329

基因治療研發市場：2024-2034

Gene Therapy R&D Market Report 2024-2034
出版日期: | 出版商: Visiongain | 英文 340 Pages | 商品交期: 最快1-2個工作天內

價格

預計到 2034 年，全球基因治療研發市場規模將以 29.8% 的複合年增長率成長。

突破、投資激增和前景廣闊的產品線正在復興基因療法並重塑醫學的未來：

在過去五年裡，基因療法取得了顯著的復興。病毒學、載體和衣殼結構以及製造方面的進步帶來了有趣的突破和監管進步，吸引了生物技術投資者的注意。生物製藥公司正在製定策略，透過擴大設施、建立合作夥伴關係以及與 CMO 合作來獲得優勢。

根據Alliance for Regenerative Medicine最近的報告，全球有超過 1,400 家公司專注於細胞和基因療法 (CGT)，有 3,500 種療法正在開發中，超過 2,000 項臨床試驗正在進行中。北美在臨床試驗方面處於領先地位，其次是亞太地區和歐洲，腫瘤和罕見疾病是主要治療目標。創投仍然是成長的主要驅動力，反映出對科學進步和潛在治療突破的熱情。

本報告調查了全球基因治療研發市場，並提供了市場概況、影響市場成長和市場機會的因素分析、市場規模趨勢和預測、各個細分市場/地區/主要國家的詳細分析以及當前的競爭資訊。狀況、主要公司簡介等

目錄

第1章 報告概述

第2章 執行摘要

第3章 市場概況

  • 主要發現
  • 市場動態
    • 市場驅動力
    • 市場制約因素
    • 市場機會
  • COVID-19 影響分析
  • 波特五力分析
  • PEST分析

第4章 基因治療研發市場分析：依疾病分類

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 癌症
  • 罕見疾病
  • 心血管疾病
  • 眼科疾病
  • 血
  • 神經系統疾病
  • 糖尿病
  • 其他
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區

第5章 基因治療研發市場分析：依載體

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 病毒
  • 非病毒
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區

第6章 基因治療研發市場分析：依技術分類

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 基因增強療法
  • 基因替代療法
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區

第7章 基因治療研發市場分析：依參與者分類

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 中小型製藥/生物技術
  • 大學和研究機構
  • 醫院/政府/公立機構
  • 大製藥公司
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區

第8章 基因治療研發市場分析：依地區

  • 主要發現
  • 市場規模趨勢和預測

第9章 北美基因治療研發市場分析

第10章 歐洲基因治療研發市場分析

第11章 亞太基因治療研發市場分析

第12章 拉丁美洲基因治療研發市場分析

第13章 中東及非洲基因治療研發市場分析

第14章 公司簡介

  • Astellas Pharma Inc.
  • American Gene Technologies
  • Beacon Therapeutics
  • Bayer
  • Benitec BioPharma
  • Biogen
  • Bluebird Bio
  • Bristol Myers Squibb
  • Calimmune, Inc.（CSL Behiring）
  • Cellectis
  • GenSight Biologics
  • Gilead Lifesciences, Inc.
  • Novartis AG
  • Orchard Therapeutics
  • Oxford Biomedica
  • Pfizer, Inc.
  • REGENXBIO Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Spark Therapeutics（Subsidiary of Roche）
  • Takeda Pharmaceuticals
  • Transgene
  • UniQure NV
  • Voyager Therapeutics
  • ViGeneron
  • GQ Bio Therapeutics GmbH
  • OCUGEN, INC.
  • Taysha GTx
  • Sarepta Therapeutics, Inc.

第15章 一般評論/建議

  • Visiongain 的一般討論
  • 對進入市場的企業的建議
Product Code: PHA1323

The global Gene Therapy R&D market is projected to grow at a CAGR of 29.8% by 2034

The Gene Therapy R&D Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Gene Therapy Resurgence Fuelled by Groundbreaking Advancements, Soaring Investments, and a Promising Pipeline Reshaping Medicine's Future

In the past five years, gene therapy has made a remarkable comeback. Advancements in virology, vector and capsid architecture, and manufacturing have led to exciting breakthroughs and regulatory progress, capturing the attention of biotech investors. Biopharma firms are strategizing to gain an edge, expanding facilities, forming partnerships, and collaborating with contract manufacturing organizations (CMOs).

According to a recent report by the Alliance for Regenerative Medicine, over 1,400 global companies are focused on cell and gene therapies (CGTs), with 3,500 therapies in development and over 2,000 active clinical trials. North America leads in clinical trials, followed by the Asia Pacific and Europe, with oncology and rare diseases as the primary therapeutic targets. Venture capital remains the main driver of growth, reflecting enthusiasm for scientific advancements and potential treatment breakthroughs.

The FDA expects to receive over 200 investigational new drug applications for CGTs annually, approving 10 to 20 new therapies per year. In 2024, up to 21 cell therapy and 31 gene therapy launches are anticipated, prompting the FDA to elevate its Office of Tissues and Advanced Therapies (OTAT) within the Center for Biologics Research and Evaluation (CBER). Proposed structural changes aim to enhance review capabilities and expertise to accommodate the growing workload and ensure efficient regulatory processes.

What Questions Should You Ask before Buying a Market Research Report?

How is the gene therapy R&D market evolving?

What is driving and restraining the gene therapy R&D market?

How will each gene therapy R&D submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each gene therapy R&D submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading gene therapy R&D markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the gene therapy R&D projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of

gene therapy R&D projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the gene therapy R&D market?

Where is the gene therapy R&D market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the gene therapy R&D market today, and over the next 10 years:

Our 340-page report provides 156 tables and 192 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the gene therapy R&D market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Disease

Cancer

Rare Diseases

Oncologic

Non-oncologic

Cardiovascular Diseases

Ophthalmic Diseases

Haematology

Neurological

Diabetes Mellitus

Other Diseases

Vector

Viral

Retrovirus

Adenovirus

AAV

Lentivirus

Others

Non-viral

Naked DNA

Gene Gun

Electroporation

Lipofection

Techniques

Gene Augmentation Therapy

Gene Replacement Therapy

Participants

Small/Medium Pharma & Biotech

Universities & Research Institutes

Hospitals

Government & Public Bodies

Big Pharma

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Gene Therapy R&D Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

American Gene Technologies

Applied Genetic

Astellas Pharma Inc.

Bayer

Benitec BioPharma

Biogen

Bluebird Bio

Bristol Myers Squibb

Calimmune, Inc. (CSL Behiring)

Cellectis

GeneQuine Biotherapeutics

GenSight Biologics

Gilead Lifesciences, Inc.

Novartis AG

Ocugen, Inc.

Orchard Therapeutics

Oxford Biomedica

Pfizer, Inc.

REGENXBIO Inc.

Sangamo Therapeutics, Inc.

Sanofi

Sarepta Therapeutics, Inc.

Spark Therapeutics (Subsidiary of Roche)

Takeda Pharmaceuticals

Taysha GTx

Transgene

UniQure N. V.

ViGeneron

Voyager Therapeutics

Overall world revenue for Gene Therapy R&D Market, 2024 to 2034 in terms of value the market will surpass US$3,600 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Gene Therapy R&D Market, 2024 to 2034 report help you?

In summary, our 340-page report provides you with the following knowledge:

Revenue forecasts to 2034 for Gene Therapy R&D Market 2024 to 2034, with forecasts for disease, vector, techniques, and participants, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 22 key national markets - See forecasts for the Gene Therapy R&D Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 29 of the major companies involved in the Gene Therapy R&D Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Gene Therapy R&D Market 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Gene Therapy R&D Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Robust Gene Therapy Pipeline to Boost Growth
      • 3.2.1.2 Technological Advancements to Fuel Market Growth
      • 3.2.1.3 Increasing Financing and Acquisitions by Major Players
      • 3.2.1.4 Growing Prevalence of Targeted Diseases Treatment
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Cell & Gene Therapies Target Specific Diseases
      • 3.2.2.2 High Cost to Stifle Gene Therapy R&D Growth
      • 3.2.2.3 Regulatory Scenarios to Challenge Industry Growth
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Growing Number of Clinical Trials to Offer Lucrative Growth Opportunities
      • 3.2.3.2 Facility Expansion Anticipated to Offer Lucrative Growth Prospects
      • 3.2.3.3 Artificial Intelligence Can Bring Value to Gene Therapy R&D
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat of Substitute Products
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis
    • 3.5.1 Political Factors Impacting Gene Therapy R&D Market
    • 3.5.2 Economic Factors Impacting Gene Therapy R&D Market
    • 3.5.3 Social Factors Impacting Gene Therapy R&D Market
    • 3.5.4 Technological Factors Impacting Gene Therapy R&D Market

4 Gene Therapy R&D Market Analysis by Disease

  • 4.1 Key Findings
  • 4.2 Disease Segment: Market Attractiveness Index
  • 4.3 Gene Therapy R&D Market Size Estimation and Forecast by Disease
  • 4.4 Cancer
    • 4.4.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Rare Diseases
    • 4.5.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Cardiovascular Diseases
    • 4.6.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)
  • 4.7 Ophthalmic Diseases
    • 4.7.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 4.7.2 Market Share by Region, 2024 & 2034 (%)
  • 4.8 Hematology
    • 4.8.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 4.8.2 Market Share by Region, 2024 & 2034 (%)
  • 4.9 Neurological
    • 4.9.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 4.9.2 Market Share by Region, 2024 & 2034 (%)
  • 4.10 Diabetes Mellitus
    • 4.10.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 4.10.2 Market Share by Region, 2024 & 2034 (%)
  • 4.11 Other Diseases
    • 4.11.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 4.11.2 Market Share by Region, 2024 & 2034 (%)

5 Gene Therapy R&D Market Analysis by Vector

  • 5.1 Key Findings
  • 5.2 Vector Segment: Market Attractiveness Index
  • 5.3 Gene Therapy R&D Market Size Estimation and Forecast by Vector
  • 5.4 Viral
    • 5.4.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Non-viral
    • 5.5.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)

6 Gene Therapy R&D Market Analysis by Techniques

  • 6.1 Key Findings
  • 6.2 Techniques Segment: Market Attractiveness Index
  • 6.3 Gene Therapy R&D Market Size Estimation and Forecast by Techniques
  • 6.4 Gene Augmentation Therapy
    • 6.4.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Gene Replacement Therapy
    • 6.5.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)

7 Gene Therapy R&D Market Analysis by Participants

  • 7.1 Key Findings
  • 7.2 Participants Segment: Market Attractiveness Index
  • 7.3 Gene Therapy R&D Market Size Estimation and Forecast by Participants
  • 7.4 Small/Medium Pharma & Biotech
    • 7.4.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Universities & Research Institutes
    • 7.5.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Hospitals, Government & Public Bodies
    • 7.6.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)
  • 7.7 Big Pharma
    • 7.7.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
    • 7.7.2 Market Share by Region, 2024 & 2034 (%)

8 Gene Therapy R&D Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Gene Therapy R&D Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Gene Therapy R&D Market Attractiveness Index
  • 9.3 North America Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 9.4 North America Gene Therapy R&D Market Size Estimation and Forecast by Country
  • 9.5 North America Gene Therapy R&D Market Size Estimation and Forecast by Disease
  • 9.6 North America Gene Therapy R&D Market Size Estimation and Forecast by Vector
  • 9.7 North America Gene Therapy R&D Market Size Estimation and Forecast by Techniques
  • 9.8 North America Gene Therapy R&D Market Size Estimation and Forecast by Participants
  • 9.9 U.S. Gene Therapy R&D Market Analysis
  • 9.10 Canada Gene Therapy R&D Market Analysis

10 Europe Gene Therapy R&D Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Gene Therapy R&D Market Attractiveness Index
  • 10.3 Europe Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 10.4 Europe Gene Therapy R&D Market Size Estimation and Forecast by Country
  • 10.5 Europe Gene Therapy R&D Market Size Estimation and Forecast by Disease
  • 10.6 Europe Gene Therapy R&D Market Size Estimation and Forecast by Vector
  • 10.7 Europe Gene Therapy R&D Market Size Estimation and Forecast by Techniques
  • 10.8 Europe Gene Therapy R&D Market Size Estimation and Forecast by Participants
  • 10.9 Germany Gene Therapy R&D Market Analysis
  • 10.10 UK Gene Therapy R&D Market Analysis
  • 10.11 France Gene Therapy R&D Market Analysis
  • 10.12 Italy Gene Therapy R&D Market Analysis
  • 10.13 Spain Gene Therapy R&D Market Analysis
  • 10.14 Russia Gene Therapy R&D Market Analysis
  • 10.15 Rest of Europe Gene Therapy R&D Market Analysis

11 Asia Pacific Gene Therapy R&D Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Gene Therapy R&D Market Attractiveness Index
  • 11.3 Asia Pacific Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 11.4 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Disease
  • 11.6 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Vector
  • 11.7 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Techniques
  • 11.8 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Participants
  • 11.9 Japan Gene Therapy R&D Market Analysis
  • 11.10 China Gene Therapy R&D Market Analysis
  • 11.11 India Gene Therapy R&D Market Analysis
  • 11.12 Australia Gene Therapy R&D Market Analysis
  • 11.13 South Korea Gene Therapy R&D Market Analysis
  • 11.14 South East Asia Gene Therapy R&D Market Analysis
  • 11.15 Rest of Asia Pacific Gene Therapy R&D Market Analysis

12 Latin America Gene Therapy R&D Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Gene Therapy R&D Market Attractiveness Index
  • 12.3 Latin America Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 12.4 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Country
  • 12.5 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Disease
  • 12.6 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Vector
  • 12.7 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Techniques
  • 12.8 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Participants
  • 12.9 Brazil Gene Therapy R&D Market Analysis
  • 12.10 Mexico Gene Therapy R&D Market Analysis
  • 12.11 Rest of Latin America Gene Therapy R&D Market Analysis

13 MEA Gene Therapy R&D Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Gene Therapy R&D Market Attractiveness Index
  • 13.3 MEA Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 13.4 MEA Gene Therapy R&D Market Size Estimation and Forecast by Country
  • 13.5 MEA Gene Therapy R&D Market Size Estimation and Forecast by Disease
  • 13.6 MEA Gene Therapy R&D Market Size Estimation and Forecast by Vector
  • 13.7 MEA Gene Therapy R&D Market Size Estimation and Forecast by Techniques
  • 13.8 MEA Gene Therapy R&D Market Size Estimation and Forecast by Participants
  • 13.9 GCC Gene Therapy R&D Market Analysis
  • 13.10 South Africa Gene Therapy R&D Market Analysis
  • 13.11 Rest of MEA Gene Therapy R&D Market Analysis

14 Company Profiles

  • 14.1 Astellas Pharma Inc.
    • 14.1.1 Company Snapshot
    • 14.1.2 Company Overview
    • 14.1.3 Financial Analysis
      • 14.1.3.1 Net Revenue, 2015-2023
      • 14.1.3.2 Regional Market Shares, 2022
      • 14.1.3.3 R&D, 2015-2023
    • 14.1.4 Product Benchmarking
  • 14.2 American Gene Technologies
    • 14.2.1 Company Snapshot
    • 14.2.2 Company Overview
    • 14.2.3 Product Benchmarking
  • 14.3 Beacon Therapeutics
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2015-2022
      • 14.3.3.2 R&D, 2015-2022
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Bayer
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2015-2023
      • 14.4.3.2 Regional Market Shares, 2023
      • 14.4.3.3 Business Segment Market Shares, 2023
      • 14.4.3.4 R&D, 2015-2023
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 Benitec BioPharma
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2015-2023
      • 14.5.3.2 R&D, 2015-2023
    • 14.5.4 Product Benchmarking
  • 14.6 Biogen
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2015-2023
      • 14.6.3.2 Regional Market Shares, 2022
      • 14.6.3.3 R&D, 2015-2023
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 Bluebird Bio
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Net Revenue, 2015-2023
      • 14.7.3.2 R&D, 2015-2023
    • 14.7.4 Product Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 Bristol Myers Squibb
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
      • 14.8.3.1 Net Revenue, 2015-2023
      • 14.8.3.2 Regional Market Shares, 2023
      • 14.8.3.3 R&D, 2015-2023
    • 14.8.4 Product Benchmarking
    • 14.8.5 Strategic Outlook
  • 14.9 Calimmune, Inc. (CSL Behiring)
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Product Benchmarking
    • 14.9.4 Strategic Outlook
  • 14.10 Cellectis
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2015-2023
      • 14.10.3.2 R&D, 2015-2023
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 GenSight Biologics
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Product Benchmarking
  • 14.12 Gilead Lifesciences, Inc.
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2015-2023
      • 14.12.3.2 R&D, 2015-2023
    • 14.12.4 Product Benchmarking
  • 14.13 Novartis AG
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2015-2023
      • 14.13.3.2 Regional Market Shares, 2023
      • 14.13.3.3 Business Segment Market Shares, 2023
      • 14.13.3.4 R&D, 2015-2023
    • 14.13.4 Product Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 Orchard Therapeutics
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Product Benchmarking
  • 14.15 Oxford Biomedica
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2015-2023
      • 14.15.3.2 Regional Market Shares, 2023
    • 14.15.4 Product Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 Pfizer, Inc.
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2015-2023
      • 14.16.3.2 Regional Market Shares, 2023
      • 14.16.3.3 Business Segment Market Shares, 2023
      • 14.16.3.4 R&D, 2015-2023
    • 14.16.4 Product Benchmarking
    • 14.16.5 Strategic Outlook
  • 14.17 REGENXBIO Inc.
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Financial Analysis
      • 14.17.3.1 Net Revenue, 2015-2023
      • 14.17.3.2 R&D, 2015-2023
    • 14.17.4 Product Benchmarking
    • 14.17.5 Strategic Outlook
  • 14.18 Sangamo Therapeutics, Inc.
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Financial Analysis
      • 14.18.3.1 Net Revenue, 2015-2023
      • 14.18.3.2 R&D, 2015-2023
    • 14.18.4 Product Benchmarking
    • 14.18.5 Strategic Outlook
  • 14.19 Sanofi
    • 14.19.1 Company Snapshot
    • 14.19.2 Company Overview
    • 14.19.3 Financial Analysis
      • 14.19.3.1 Net Revenue, 2015-2023
      • 14.19.3.2 Regional Market Shares, 2023
      • 14.19.3.3 R&D, 2015-2023
    • 14.19.4 Product Benchmarking
    • 14.19.5 Strategic Outlook
  • 14.20 Spark Therapeutics (Subsidiary of Roche)
    • 14.20.1 Company Snapshot
    • 14.20.2 Company Overview
    • 14.20.3 Product Benchmarking
    • 14.20.4 Strategic Outlook
  • 14.21 Takeda Pharmaceuticals
    • 14.21.1 Company Snapshot
    • 14.21.2 Company Overview
    • 14.21.3 Financial Analysis
      • 14.21.3.1 Net Revenue, 2015-2023
      • 14.21.3.2 R&D, 2015-2023
    • 14.21.4 Product Benchmarking
    • 14.21.5 Strategic Outlook
  • 14.22 Transgene
    • 14.22.1 Company Snapshot
    • 14.22.2 Company Overview
    • 14.22.3 Product Benchmarking
  • 14.23 UniQure NV
    • 14.23.1 Company Snapshot
    • 14.23.2 Company Overview
    • 14.23.3 Financial Analysis
      • 14.23.3.1 Net Revenue, 2015-2023
      • 14.23.3.2 R&D, 2015-2023
    • 14.23.4 Product Benchmarking
    • 14.23.5 Strategic Outlook
  • 14.24 Voyager Therapeutics
    • 14.24.1 Company Snapshot
    • 14.24.2 Company Overview
    • 14.24.3 Financial Analysis
      • 14.24.3.1 Net Revenue, 2015-2023
      • 14.24.3.2 R&D, 2015-2023
    • 14.24.4 Product Benchmarking
    • 14.24.5 Strategic Outlook
  • 14.25 ViGeneron
    • 14.25.1 Company Snapshot
    • 14.25.2 Company Overview
    • 14.25.3 Product Benchmarking
    • 14.25.4 Strategic Outlook
  • 14.26 GQ Bio Therapeutics GmbH
    • 14.26.1 Company Snapshot
    • 14.26.2 Company Overview
    • 14.26.3 Product Benchmarking
    • 14.26.4 Strategic Outlook
  • 14.27 OCUGEN, INC.
    • 14.27.1 Company Snapshot
    • 14.27.2 Company Overview
    • 14.27.3 Product Benchmarking
    • 14.27.4 Strategic Outlook
  • 14.28 Taysha GTx
    • 14.28.1 Company Snapshot
    • 14.28.2 Company Overview
    • 14.28.3 Product Benchmarking
  • 14.29 Sarepta Therapeutics, Inc.
    • 14.29.1 Company Snapshot
    • 14.29.2 Company Overview
    • 14.29.3 Product Benchmarking
    • 14.29.4 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players

List of Tables

  • Table 1 Cell and Gene Therapy Landscape
  • Table 2 Gene Therapy R&D Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
  • Table 3 Cell and Gene Therapy Landscape
  • Table 4 Cell and Gene Therapy Landscape
  • Table 5 Cell and Gene Therapy Landscape
  • Table 6 Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "V" Shaped Recovery
  • Table 7 Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "U" Shaped Recovery
  • Table 8 Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "W" Shaped Recovery
  • Table 9 Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "L" Shaped Recovery
  • Table 10 Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 11 Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 12 Rare Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 13 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 14 Ophthalmic Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 15 Hematology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 16 Neurological Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 17 Diabetes Mellitus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 18 Other Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 19 Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 20 Pharmaceutical & Biotechnology Companies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 21 Non-viral Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 22 Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 23 Gene Augmentation Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 24 Gene Replacement Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 25 Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 26 Small/Medium Pharma & Biotech Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 27 Universities Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 28 Hospitals, Government & Public Bodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 29 Big Pharma Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 30 Global Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 31 North America Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 32 North America Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 33 North America Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 34 North America Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 35 North America Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 36 U.S. Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 37 Canada Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 38 Europe Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 39 Europe Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 40 Europe Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 41 Europe Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 42 Europe Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 43 Germany Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 44 UK Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 45 France Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 46 Italy Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 47 Spain Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 48 Russia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 49 Rest of Europe Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 50 Asia Pacific Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 51 Asia Pacific Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 52 Asia Pacific Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 53 Asia Pacific Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 54 Asia Pacific Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 55 Japan Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 56 China Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 57 India Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 58 Australia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 59 South Korea Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 60 South East Asia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 61 Rest of Asia Pacific Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 62 Latin America Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 63 Latin America Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 64 Latin America Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 65 Latin America Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 66 Latin America Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 67 Brazil Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 68 Mexico Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 69 Rest of Latin America Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 70 MEA Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 71 MEA Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 72 MEA Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 73 MEA Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 74 MEA Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 75 GCC Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 76 South Africa Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 77 Rest of MEA Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 78 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 79 Astellas Pharma Inc.: Product Benchmarking
  • Table 80 American Gene Technologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 81 American Gene Technologies: Product Benchmarking
  • Table 82 Beacon Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 83 Beacon Therapeutics: Product Benchmarking
  • Table 84 Beacon Therapeutics: Strategic Outlook
  • Table 85 Bayer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 86 Bayer: Product Benchmarking
  • Table 87 Bayer: Strategic Outlook
  • Table 88 Benitec BioPharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 89 Benitec BioPharma: Product Benchmarking
  • Table 90 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 Biogen: Product Benchmarking
  • Table 92 Biogen: Strategic Outlook
  • Table 93 Bluebird Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 Bluebird Bio: Product Benchmarking
  • Table 95 Bluebird Bio: Strategic Outlook
  • Table 96 Bristol Myers Squibb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 Bristol Myers Squibb: Product Benchmarking
  • Table 98 Bristol Myers Squibb: Strategic Outlook
  • Table 99 Calimmune, Inc. (CSL Behiring): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 Calimmune, Inc. (CSL Behiring): Product Benchmarking
  • Table 101 Calimmune, Inc. (CSL Behiring): Strategic Outlook
  • Table 102 Cellectis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 Cellectis: Product Benchmarking
  • Table 104 Cellectis: Strategic Outlook
  • Table 105 GenSight Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 106 GenSight Biologics: Product Benchmarking
  • Table 107 Gilead Lifesciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 108 Gilead Lifesciences, Inc.: Product Benchmarking
  • Table 109 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 110 Novartis AG: Product Benchmarking
  • Table 111 Novartis AG: Strategic Outlook
  • Table 112 Orchard Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 113 Orchard Therapeutics: Product Benchmarking
  • Table 114 Oxford Biomedica: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 115 Oxford Biomedica: Product Benchmarking
  • Table 116 Oxford Biomedica: Strategic Outlook
  • Table 117 Pfizer, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 118 Pfizer, Inc.: Product Benchmarking
  • Table 119 Pfizer, Inc.: Strategic Outlook
  • Table 120 REGENXBIO Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 121 REGENXBIO Inc.: Product Benchmarking
  • Table 122 REGENXBIO Inc.: Strategic Outlook
  • Table 123 Sangamo Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 124 Sangamo Therapeutics, Inc.: Product Benchmarking
  • Table 125 Sangamo Therapeutics, Inc.: Strategic Outlook
  • Table 126 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 127 Sanofi: Product Benchmarking
  • Table 128 Sanofi: Strategic Outlook
  • Table 129 Spark Therapeutics (Subsidiary of Roche): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 130 Spark Therapeutics (Subsidiary of Roche): Product Benchmarking
  • Table 131 Spark Therapeutics (Subsidiary of Roche): Strategic Outlook
  • Table 132 Takeda Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 133 Takeda Pharmaceuticals: Product Benchmarking
  • Table 134 Takeda Pharmaceuticals: Strategic Outlook
  • Table 135 Transgene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 136 Transgene: Product Benchmarking
  • Table 137 UniQure NV: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 138 UniQure NV: Product Benchmarking
  • Table 139 UniQure NV: Strategic Outlook
  • Table 140 Voyager Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 141 Voyager Therapeutics: Product Benchmarking
  • Table 142 Voyager Therapeutics: Strategic Outlook
  • Table 143 ViGeneron: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 144 ViGeneron: Product Benchmarking
  • Table 145 ViGeneron: Strategic Outlook
  • Table 146 GQ Bio Therapeutics GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 147 GQ Bio Therapeutics GmbH: Product Benchmarking
  • Table 148 GQ Bio Therapeutics GmbH: Strategic Outlook
  • Table 149 OCUGEN, INC.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 150 OCUGEN, INC.: Product Benchmarking
  • Table 151 OCUGEN, INC.: Strategic Outlook
  • Table 152 Taysha GTx: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 153 Taysha GTx: Product Benchmarking
  • Table 154 Sarepta Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 155 Sarepta Therapeutics, Inc.: Product Benchmarking
  • Table 156 Sarepta Therapeutics, Inc.: Strategic Outlook

List of Figures

  • Figure 1 Gene Therapy R&D Market Segmentation
  • Figure 2 Gene Therapy R&D Market by Disease: Market Attractiveness Index
  • Figure 3 Gene Therapy R&D Market by Vector: Market Attractiveness Index
  • Figure 4 Gene Therapy R&D Market by Techniques: Market Attractiveness Index
  • Figure 5 Gene Therapy R&D Market by Participants: Market Attractiveness Index
  • Figure 6 Gene Therapy R&D Market Attractiveness Index by Region
  • Figure 7 Gene Therapy R&D Market: Market Dynamics
  • Figure 8 Number of Therapies from Preclinical Through Pre-registration till January 2024
  • Figure 9 Total Number of Deals by Type
  • Figure 10 Volume and Dollar Value of Series A and Seed Financings for Gene, Cell, & RNA Therapy Companies
  • Figure 11 Gene Therapy R&D Market by Region, 2024-2034 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 12 Gene Therapy R&D Market by Region, 2024-2034 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 13 Gene Therapy R&D Market by Region, 2024-2034 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 14 Gene Therapy R&D Market by Region, 2024-2034 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 15 Gene Therapy R&D Market: Porter's Five Forces Analysis
  • Figure 16 Gene Therapy R&D Market: PEST Analysis
  • Figure 17 Gene Therapy R&D Market Attractiveness Index by Disease
  • Figure 18 Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
  • Figure 19 Gene Therapy R&D Market Share Forecast by Disease, 2024, 2029, 2034 (%)
  • Figure 20 Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 21 Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 22 Rare Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 23 Rare Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 24 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 25 Cardiovascular Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 26 Ophthalmic Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 27 Ophthalmic Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 28 Hematology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 29 Hematology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 30 Neurological Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 31 Neurological Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 32 Diabetes Mellitus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 33 Diabetes Mellitus Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 34 Other Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 35 Other Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 36 Gene Therapy R&D Market Attractiveness Index by Disease
  • Figure 37 Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
  • Figure 38 Gene Therapy R&D Market Share Forecast by Vector, 2024, 2029, 2034 (%)
  • Figure 39 Viral Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 40 Viral Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 41 Non-viral Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 42 Non-viral Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 43 Gene Therapy R&D Market Attractiveness Index by Techniques
  • Figure 44 Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
  • Figure 45 Gene Therapy R&D Market Share Forecast by Techniques, 2024, 2029, 2034 (%)
  • Figure 46 Gene Augmentation Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 47 Gene Augmentation Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 48 Gene Replacement Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 49 Gene Replacement Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Gene Therapy R&D Market Attractiveness Index by Participants
  • Figure 51 Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
  • Figure 52 Gene Therapy R&D Market Share Forecast by Participants, 2024, 2029, 2034 (%)
  • Figure 53 Small/Medium Pharma & Biotech Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 54 Small/Medium Pharma & Biotech Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 55 Universities & Research Institutes Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 56 Universities & Research Institutes Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 57 Hospitals, Government & Public Bodies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 58 Hospitals, Government & Public Bodies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 59 Big Pharma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 60 Big Pharma Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 61 Gene Therapy R&D Market Forecast by Region 2024, 2029, 2034 (Revenue, CAGR%)
  • Figure 62 Gene Therapy R&D Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 63 Gene Therapy R&D Market by Region, 2024-2034 (US$ Mn)
  • Figure 64 North America Gene Therapy R&D Market Attractiveness Index
  • Figure 65 North America Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
  • Figure 66 North America Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 67 North America Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 68 North America Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
  • Figure 69 North America Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 70 North America Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
  • Figure 71 North America Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
  • Figure 72 North America Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
  • Figure 73 North America Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
  • Figure 74 North America Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
  • Figure 75 North America Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
  • Figure 76 U.S. Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 77 Canada Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 78 Europe Gene Therapy R&D Market Attractiveness Index
  • Figure 79 Europe Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
  • Figure 80 Europe Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 81 Europe Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 82 Europe Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
  • Figure 83 Europe Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 84 Europe Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
  • Figure 85 Europe Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
  • Figure 86 Europe Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
  • Figure 87 Europe Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
  • Figure 88 Europe Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
  • Figure 89 Europe Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
  • Figure 90 Germany Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 91 UK Fund Raising to 31st October 2023
  • Figure 92 UK Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 93 France Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 94 Italy Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 95 Spain Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 96 Russia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 97 Rest of Europe Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 98 Asia Pacific Gene Therapy R&D Market Attractiveness Index
  • Figure 99 Asia Pacific Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
  • Figure 100 Asia Pacific Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 101 Asia Pacific Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 102 Asia Pacific Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
  • Figure 103 Asia Pacific Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 104 Asia Pacific Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
  • Figure 105 Asia Pacific Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
  • Figure 106 Asia Pacific Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
  • Figure 107 Asia Pacific Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
  • Figure 108 Asia Pacific Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
  • Figure 109 Asia Pacific Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
  • Figure 110 Japan Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 111 China Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 112 India Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 113 Australia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 114 South Korea Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 115 South East Asia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 116 Rest of Asia Pacific Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 117 Latin America Gene Therapy R&D Market Attractiveness Index
  • Figure 118 Latin America Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
  • Figure 119 Latin America Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 120 Latin America Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 121 Latin America Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
  • Figure 122 Latin America Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 123 Latin America Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
  • Figure 124 Latin America Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
  • Figure 125 Latin America Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
  • Figure 126 Latin America Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
  • Figure 127 Latin America Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
  • Figure 128 Latin America Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
  • Figure 129 Brazil Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 130 Mexico Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 131 Rest of Latin America Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 132 MEA Gene Therapy R&D Market Attractiveness Index
  • Figure 133 MEA Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
  • Figure 134 MEA Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 135 MEA Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 136 MEA Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
  • Figure 137 MEA Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 138 MEA Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
  • Figure 139 MEA Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
  • Figure 140 MEA Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
  • Figure 141 MEA Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
  • Figure 142 MEA Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
  • Figure 143 MEA Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
  • Figure 144 GCC Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 145 South Africa Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 146 Rest of MEA Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 147 Astellas Pharma Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 148 Astellas Pharma Inc.: Regional Market Shares (%), 2022
  • Figure 149 Astellas Pharma Inc.: R&D, 2015-2023 (US$ Million, AGR %)
  • Figure 150 Beacon Therapeutics: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 151 Beacon Therapeutics: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 152 Bayer: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 153 Bayer: Regional Market Shares (%), 2023
  • Figure 154 Bayer: Business Segment Market Shares, 2023
  • Figure 155 Bayer: R&D, 2015-2023 (US$ million, AGR %)
  • Figure 156 Benitec BioPharma: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 157 Benitec BioPharma: R&D, 2015-2023 (US$ Million, AGR %)
  • Figure 158 Biogen: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 159 Biogen: Regional Market Shares (%), 2022
  • Figure 160 Biogen: R&D, 2015-2023 (US$ Million, AGR %)
  • Figure 161 Bluebird Bio: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 162 Bluebird Bio: R&D, 2015-2023 (US$ Million, AGR %)
  • Figure 163 Bristol Myers Squibb: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 164 Bristol Myers Squibb: Regional Market Shares (%), 2023
  • Figure 165 Bristol Myers Squibb: R&D, 2015-2023 (US$ Million, AGR %)
  • Figure 166 Cellectis: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 167 Cellectis: R&D, 2015-2023 (US$ Million, AGR %)
  • Figure 168 Gilead Lifesciences, Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 169 Gilead Lifesciences, Inc.: R&D, 2015-2023 (US$ Million, AGR %)
  • Figure 170 Novartis AG: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 171 Novartis AG: Regional Market Shares (%), 2023
  • Figure 172 Novartis AG: Business Segment Market Shares, 2023
  • Figure 173 Novartis AG: R&D, 2015-2023 (US$ million, AGR %)
  • Figure 174 Oxford Biomedica: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 175 Oxford Biomedica: Regional Market Shares (%), 2023
  • Figure 176 Pfizer, Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 177 Pfizer, Inc.: Regional Market Shares (%), 2023
  • Figure 178 Pfizer, Inc.: Business Segment Market Shares, 2023
  • Figure 179 Pfizer, Inc.: R&D, 2015-2023 (US$ Million, AGR %)
  • Figure 180 REGENXBIO Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 181 REGENXBIO Inc.: R&D, 2015-2023 (US$ Million, AGR %)
  • Figure 182 Sangamo Therapeutics, Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 183 Sangamo Therapeutics, Inc.: R&D, 2015-2023 (US$ Million, AGR %)
  • Figure 184 Sanofi: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 185 Sanofi: Regional Market Shares (%), 2023
  • Figure 186 Sanofi: R&D, 2015-2023 (US$ Million, AGR %)
  • Figure 187 Takeda Pharmaceuticals: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 188 Takeda Pharmaceuticals: R&D, 2015-2023 (US$ Million, AGR %)
  • Figure 189 UniQure NV: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 190 UniQure NV: R&D, 2015-2023 (US$ Million, AGR %)
  • Figure 191 Voyager Therapeutics: Net Revenue, 2015-2023 (US$ Million, AGR %)
  • Figure 192 Voyager Therapeutics: R&D, 2015-2023 (US$ Million, AGR %)